Johnson & Johnson Romania together with "Carol Davila" University of Medicine and Pharmacy in Bucharest (UMFCD), through the Center for Innovation and eHealth and the Medical Students' Society of Bucharest, announce the organizing of the fourth edition of Hackathon4Health.
For the fourth consecutive year, the project’s strategic partners of the project are the U.S. Embassy in Romania and the American Chamber of Commerce in Romania (AmCham Romania).
The event will take place between December 11 – 13 in digital format and will bring together healthcare experts, representatives of the authorities, medical and hospital service providers, academic field and business, medical students and students at other faculties of concern, technical specialists and representatives of patient associations, to develop innovative digital solutions designed to improve the quality of life in Romania and develop the digital healthcare ecosystem at national level.
The suggested themes for this edition are:
„Hackathon4Health 2020 has become a catalyst for innovative ideas and bringing together technology enthusiasts, academics, entrepreneurs, patients and health professionals. The digital solutions developed in the last three editions are an important engine for the digital transformation of health in Romania and we are glad that at Johnson & Johnson Romania, together with our partners, we constantly create solutions for innovation and development”, says Sévan Kaloustian, Managing Director at Janssen, the pharmaceutical company of Johnson & Johnson in Romania.
This year, the event initiated by Johnson & Johnson Romania is implemented in collaboration with "Carol Davila" University of Medicine and Pharmacy in Bucharest (UMFCD) through the Center for Innovation and eHealth, with which Johnson & Johnson Romania recently signed a partnership in the eHealth area, and the Bucharest Medical Students Society.
"To have the chance to work on a project with a real healthcare impact and to benefit from the professional advice and guidance of specialists in both medical and technology fields - these are extraordinary benefits for medical students and they will significantly contribute to their future development as professionals and important players in the healthcare sector. I congratulate and support this approach of Johnson & Johnson Romania especially since, this year, we have fully felt the need for digitalization in healthcare and education, as two important pillars for the functioning of society", says Prof. Dr. Viorel Jinga, Rector of "Carol Davila" University of Medicine and Pharmacy in Bucharest.
The event will take place live over two days on a dedicated digital platform where participants will work in teams and receive help from mentors, experts and healthcare professionals, IT&C, academic, entrepreneurship and representatives of the authorities in Romania, in every aspect related to the field of medical information, access and healthcare system, but also technical support for the implementation of solutions. At the end of the two days, the teams will present their projects and 3 winning projects chosen by the jury will receive each a $5,000 pre-seed funding from Johnson & Johnson and 6-months mentoring from the company and the "Carol Davila" University of Medicine and Pharmacy in Bucharest (UMFCD) through the Center for Innovation and eHealth. Following the 3 previous editions, 9 winning teams were chosen whose innovative health solutions have already been launched for use or are in advanced stages of implementation.
About Johnson & Johnson
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity. Learn more at www.jnj.com. Follow us at @JNJNews.
About the Janssen Pharmaceutical Companies
At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. Learn more at www.janssen.com. Follow us at @JanssenGlobal.
About Center for Innovation and eHealth
CieH is a structure within UMFCD that helps students and doctors develop skills and competence in innovation and digital health, in order to increase competitiveness and adapt to the digitalization of education and healthcare systems. CieH aims to develop digital and innovative solutions to serve all actors involved in the healthcare sector. CieH supports the technological transfer of viable solutions and the capitalization and dissemination of their results. For more information, visit cieh.umfcd.ro. Follow us on @CieHUMFCD.
Precautions regarding forward-looking statements
This press release contains "forward-looking statements" as defined in the Securities Litigation Reform Act of 1995 on the development of potential prevention and treatment schemes for COVID-19. Readers are cautioned not to rely on these forward-looking statements. These statements are based on current expectations about future events. If the underlying assumptions prove inaccurate and the known or unknown risks or uncertainties materialize, actual results could significantly differ from the expectations and projections of Janssen, part of the group of Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success; production difficulties and delays; competition, including technological developments, new products and patents obtained by competitors; patent challenges; and trends in reducing healthcare costs. An additional list and descriptions of these risks, uncertainties and other factors can be found in the Johnson & Johnson Annual Report on Form 10-K for the fiscal year ended December 29, 2019, including the “Cautionary Note on forward-looking Statements” sections and “Point 1A. Risk Factors,” and in the company's most recent Quarterly Report filed on the basis of Form 10-Q and subsequent company records with the Securities and Exchange Commission. Copies of these submissions are available online at www.sec.gov, www.jnj.com or upon request from Johnson & Johnson. Neither Janssen nor Johnson & Johnson Pharmaceutical Companies undertakes to update any forward-looking statements as a result of new information or future events or developments.